This segment focuses on the research and development of extended half-life monoclonal antibodies for the treatment of atopic dermatitis (AD). The primary focus is on APG777, a subcutaneous (SQ) mAb designed for improved efficacy and reduced dosing frequency. Research and development activities include preclinical studies, Phase 1 and Phase 2 clinical trials, and formulation development. The segment utilizes advanced antibody engineering and protein optimization technologies. The goal is to provide a safe and effective treatment option for AD patients, improving their quality of life by reducing symptoms and disease burden. Market positioning involves targeting the large and growing AD market, with a focus on differentiating APG777 through its extended half-life and potential for improved patient adherence. Future opportunities include expanding the AD pipeline with additional candidates like APG990 and APG222, and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials to demonstrate safety and efficacy. Partnerships and collaborations may be pursued to accelerate development and commercialization.

This segment is dedicated to the development of APG808, an SQ extended half-life mAb for the treatment of chronic obstructive pulmonary disease (COPD). Research and development efforts include preclinical studies, clinical trials, and formulation development. The segment leverages advanced antibody engineering and protein optimization technologies to create a long-acting therapeutic. The aim is to provide a more convenient and effective treatment option for COPD patients, potentially reducing exacerbations and improving lung function. Market positioning involves targeting the COPD market, with a focus on the differentiated profile of APG808. Future opportunities include exploring combination therapies and expanding the COPD pipeline. Regulatory and clinical aspects involve obtaining necessary approvals and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations may be considered to accelerate development and commercialization.